EUVIMEDEUVIMED entdecken
Crossref

Targeting the CCL2–CCR2 axis in cancer: insights into in vitro screening and humanized mice

Yanjun Chen, Midori Shimada

The Journal of Biochemistry · 2026

DOI: 10.1093/jb/mvag009 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Biochemistry, 2026. Verfasst von Yanjun Chen und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biology, Graduate School of Medicine, Nagoya University, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8560, Japan. Hauptthemen laut MEDLINE: Receptors, CCR2, Chemokine CCL2, Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 19 Literaturangaben. Gefördert von: Fusion Oriented REsearch for disruptive Science and Technology, Canon Medical Systems Corporation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

An immunosuppressive tumor microenvironment that facilitates cancer progression is an important challenge in combating the disease. The CCL2–CCR2 axis is a primary facilitator in this process, facilitating the recruitment of CCR2-positive myeloid cells, including M-MDSCs and TAMs, to tumor and metastatic locations. CCR2 is also expressed on tumor cells and regulatory T cells, further enhancing cancer cell motility and immune suppression. Inhibition of this system through genetic deletion or small-molecule inhibitors significantly reduces primary tumor and metastasis in preclinical models, highlighting CCR2 as a promising therapeutic target. Although several CCR2 inhibitors have entered clinical trials, differences in their potency and the limited predictability of murine models have hampered clinical translation. The current work by Sugiyama et al. carefully evaluated 10 human CCR2 antagonists, identifying MK0812 as the most effective inhibitor. Using human CCR2B knock-in mice, they established a practical platform for evaluating CCR2-targeted drugs with direct relevance to human cancer therapy, highlighting the importance of humanized models for translational immuno-oncology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, CCR2Chemokine CCL2NeoplasmsAntineoplastic AgentsAnimalsHumansMiceTumor Microenvironment

Stichwörter der Autor:innen

CCL2-CCR2 axisdrug screening assaysin vitroknock-in micemonocytic myeloid-derived suppressor cells (M-MDSCs)tumor microenvironment

Substanzen

Receptors, CCR2Chemokine CCL2CCR2 protein, humanCCL2 protein, humanAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Molecular Biology, Graduate School of Medicine, Nagoya University, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8560, Japan.

Förderung

  • Fusion Oriented REsearch for disruptive Science and Technology
  • Canon Medical Systems Corporation

Zitieren

APA

Chen, Y., & Shimada, M. (2026). Targeting the CCL2–CCR2 axis in cancer: insights into in vitro screening and humanized mice. The Journal of Biochemistry. https://doi.org/10.1093/jb/mvag009

Vancouver

Chen Y, Shimada M. Targeting the CCL2–CCR2 axis in cancer: insights into in vitro screening and humanized mice. The Journal of Biochemistry. 2026. doi:10.1093/jb/mvag009

BibTeX
@article{Chen2026,
  author = {Chen, Yanjun and Shimada, Midori},
  title = {Targeting the CCL2–CCR2 axis in cancer: insights into in vitro screening and humanized mice},
  journal = {The Journal of Biochemistry},
  year = {2026},
  doi = {10.1093/jb/mvag009}
}
Kostenlos starten →